A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to produce protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with immediate protection from the point of delivery, precisely when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent protection when vaccinated 4 weeks before birth
- Maternal antibodies transferred through the placenta safeguard newborns from birth
- Coverage achievable with 2-week gap before premature birth
- Vaccination during the third trimester still provides meaningful protection for infants
Compelling evidence from recent research
The performance of the RSV vaccine administered during pregnancy has been confirmed through a thorough investigation carried out throughout England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month period, providing comprehensive and reliable data of the vaccine’s practical effectiveness. The study’s results have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scale of this research offers healthcare professionals and parents-to-be with trust in the vaccine’s proven efficacy across different groups and contexts.
The results paint a striking picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This marked difference underscores the vaccine’s essential role in preventing serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology captured actual clinical results rather than experimental conditions, providing tangible evidence of how the vaccine works when delivered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its hazards
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during peak seasons.
The infection produces inflammation deep within the lungs and airways, making it extremely challenging for affected infants to breathe and feed properly. Parents commonly see their babies struggling visibly, their chests heaving as they try to pull adequate oxygen into their weakened respiratory system. Whilst most newborns improve through palliative treatment, a small but significant number die from RSV-related complications yearly, making immunisation programmes a critical public health priority for protecting the youngest and most at-risk people in our communities.
- RSV produces lung inflammation, causing severe breathing difficulties in infants
- Approximately half of infants acquire the virus during their first few months alive
- Symptoms span from mild colds to serious chest infections that threaten life requiring hospitalisation
- More than 20,000 UK infants require serious hospital care for RSV annually
- Small numbers of infants die from RSV complications each year in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have stressed the significance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to maximise the antibodies passed to their babies via the placenta.
The messaging from public health bodies remains clear: pregnant women should prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Some areas have attained higher vaccination coverage among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These geographical variations reflect variations in medical facilities, communication strategies, and community involvement initiatives, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts launching varied communication campaigns to engage with pregnant women
- Regional disparities in immunisation take-up across England require targeted improvement
- Community health services adapting programmes to align with local requirements and situations
Practical implications and parent viewpoints
The vaccine’s outstanding effectiveness provides tangible benefits for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the rollout of this preventative solution, the 80% decrease in admissions equates to thousands of infants shielded from serious illness. Parents no more face the upsetting situation of watching their newborns struggle for breath or struggle to eat, symptoms that define severe RSV infections. The vaccine has markedly changed the picture of neonatal lung health, giving expectant mothers a active means to shield their most vulnerable children during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection led to devastating brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s support of the jab highlights the life-altering consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to expectant mothers navigating their final trimester, changing what was once an unavoidable seasonal threat into a manageable health risk.